Upregulation of ADAM-17 expression in active lesions in multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 4, 2006, Pages 375-385

  Plumb, J ^a   McQuaid, S ^b   Cross, A K ^a   Surr, J ^a   Haddock, G ^a   Bunning, R A D ^a   Woodroofe, M N ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

ADAM 17; Adhesion molecules; Astrocytes; Endothelium; Multiple sclerosis; TACE; Tumour necrosis factor

Indexed keywords

MYELIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; AGED; ARTICLE; ASTROCYTE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; WHITE MATTER;

ADAM PROTEINS; AGED; AGED, 80 AND OVER; ASTROCYTES; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN SHEATH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION;

EID: 33746540980     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1276oa     Document Type: Article

References (57)

1. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33.
2. Black RA. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002; 34: 1-5.
3. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL et al. Cloning of a disintegrin metallo-proteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385: 733-36.
4. Killar L, White J, Black R, Peschon J. Adamalysins: a family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999; 878: 442-52.
5. Schlondorff J, Lum L, Blobel CP. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem 2001; 276: 14665-74.
6. Itai T, Tanaka M, Nagata S. Processing of tumor necrosis factor by the membrane-bound TNF-alpha-converting enzyme, but not its truncated soluble form. Eur J Biochem 2001; 268: 2074-82.
7. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 2003; 278: 32801-809.
8. Dri P, Gasparini C, Menegazzi R, Cramer R, Alberi L, Presani G et al. TNF-induced shedding of TNF receptors in human polymorphonuclear leukocytes: role of the 55-kDa TNF receptor and involvement of a membrane-bound and non-matrix metalloproteinase. J Immunol 2000; 165: 2165-72.
9. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993-8001.
10. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 2003; 278: 37459-64.
11. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943-52.
12. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000; 275: 14608-14.
13. Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello Sbarba P. TNF-alpha-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol 2001; 166: 1583-89.
14. Borland G, Murphy G, Ager A. Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes. J Biol Chem 1999; 274: 2810-15.
15. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 2003; 74: 342-52.
16. Brosnan CF, Selmaj K, Raine CS. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol 1988; 18: 87-94.
17. Cimini A, Bernardo A, Cifone MG, Di Marzio L, Di Loreto S, Cifone G et al. TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 2003; 41: 3-14.
18. Gerspach J, Gotz A, Zimmermann G, Kolle C, Bottinger H, Grell M. Detection of membrane-bound tumor necrosis factor (TNF): an analysis of TNF-specific reagents. Microsc Res Tech 2000; 50: 243-50.
19. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
20. Corazza N, Brunner T, Buri C, Rihs S, Imboden MA, Seibold I et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 2004; 127: 816-25.
21. Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G, Probert L. Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci U S A 2003; 100: 709-14.
22. Milla ME, Leesnitzer MA, Moss ML, Clay WC, Carter HL, Miller AB et al. Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE). J Biol Chem 1999; 274: 30563-70.
23. Amour A, Slocombe PM, Webster A, Butler M, Knight CG et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 39-44.
24. Ozenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisakk P, Kouwenhoven M et al. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun 1999; 12: 297-303.
25. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275: 31226-32.
26. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metallo-proteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 1998; 152: 729-41.
27. Jaworski DM, Eager N. Regulation of tissue inhibitor of metalloproteinase-3 (TIMP-3) mRNA expression during rat CNS development. J Neurosci Res 2000; 61: 396-408.
28. Vaillant C, Didier-Bazes M, Hutter A, Belin M-F, Thomasset N. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J Neurosci 1999; 19: 4994-5004.
29. Goddard DR, Bunning RA, Woodroofe MN. Astrocyte and endothelial cell expression of ADAM 17 (TACE) in adult human CNS. Glia 2001; 34: 267-71.
30. Kieseier BC, Pischel H, Neuen-Jacob E, Tourtellotte WW, Hartung HP. ADAM-10 and ADAM-17 in the inflamed human CNS. Glia 2003; 42: 398-405.
31. Karkkainen I, Rybnikova E, Pelto-Huikko M, Huovila AP. Metalloprotease-disintegrin (ADAM) genes are widely and differentially expressed in the adult CNS. Mol Cell Neurosci 2000; 15: 547-60.
32. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W et al. The tumour necrosis factor-α converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 2002; 41: 942-69.
33. Duan JJ, Lu Z, Xue CB, He X, Seng JL, Roderick JJ et al. Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Lett 2003; 13: 2035-40.
34. Baugh JA, Bucala R. Mechanisms for modulating TNF alpha in immune and inflammatory disease. Curr Opin Drug Discov Devel 2001; 4: 635-50.
35. Cherney RJ, Duan JJ, Voss ME, Chen L, Wang L, Meyer DT et al. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors. J Med Chem 2003; 46: 1811-23.
36. Sanders V, Conrad AK, Tourtellotte WW. On classification of post-mortem multiple sclerosis plaques for neuroscientists. J Neuroimmunol 1993; 46: 201-16.
37. van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000; 26: 2-10.
38. Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002; 12: 154-69.
39. Kirk J, Plumb J, Mirakhur M, McQuaid S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003; 201: 319-27.
40. Hurtado O, Cardenas A, Lizasoain I, Bosca L, Leza. JC, Lorenzo P et al. Up-regulation of TNF-α convertase (TACE/ADAM-17) after oxygen-glucose deprivation in rat forebrain slices. Neuropharmacology 2001; 40: 1094-102.
41. Peiretti F, Canault M, Deprez-Beauclair P, Berthet V, Bonardo B, Juhan-Vague I et al. Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme. Exp Cell Res 2003; 285: 278-85.
42. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-12.
43. Dobbie MS, Hurst RD, Klein NJ, Surtees RA. Upregulation of intercellular adhesion molecule-1 expression on human endothelial cells by tumour necrosis factor-alpha in an in vitro model of the blood-brain barrier. Brain Res 1999; 2: 330-36.
44. Probert L, Akassoglou K. Glial expression of tumor necrosis factor in transgenic animals: How do these models reflect the "normal situation"? Glia 2001; 36: 212-19.
45. Weishaupt A, Kreiss M, Gold R, Herrmann T. Modulation of experimental autoimmune encephalo-myelitis by administration of cells expressing antigenic peptide covalently linked to MHC class II. J Neuroimmunol 2004; 152: 11-19.
46. Etienne-Manneville S, Manneville JB, Adamson P, Wilbourn B, Greenwood J, Courand PO. ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J Immunol 2000; 6: 3375-83.
47. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990; 6: 1309-16.
48. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994; 1: 89-97.
49. Wong D, Dorovini-Zis K. Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide. J Neuroimmunol 1992; 1-2: 11-21.
50. Wong D, Dorovini-Zis K. Expression of vascular cell adhesion molecule-1 (VCAM-1) by human brain micro-vessel endothelial cells in primary culture. Microvasc Res 1995; 3: 325-39.
51. Martino G, Consiglio A, Franciotta DM, Corti A, Filippi M, Vandenbroeck K et al. Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis. J Neurol Sci 1997;152: 51-61.
52. Lindberg RLP, De Groot CJA, Montange L, Freitag P, van der Valk P, Kappos L et al. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 2001; 124: 1743-53.
53. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang C-L et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998; 153: 1895-902.
54. Crocker SJ, Pagenstecher A, Campbell IL. The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res 2004; 75: 1-14.
55. Plumb J, Cross AR, Surr J, Haddock G, Smith T, Bunning RAD et al. ADAM-17 protein and mRNA expression in the spinal cord of rats with acute experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 164: 1-9.
56. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated anti-TNF therapy. Neurology 2001; 57: 1885-88.
57. Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-34.